NCT05039073View on ClinicalTrials.gov

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 2, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HSCT

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

RECRUITING

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER